The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Industrialization of mAb production technology: The bioprocessing industry at a crossroads
Open accessAbstract
Manufacturing processes for therapeutic monoclonal antibodies (mAbs) have evolved tremendously since the first licensed mAb product in 1986. The rapid growth in product demand for mAbs triggered parallel efforts to increase production capacity through construction of large bulk manufacturing plants as well as improvements in cell culture processes to raise product titers. This combination has led to an excess of manufacturing capacity, and together with improvements in conventional purification technologies, promises nearly unlimited production capacity in the foreseeable future. The increase in titers has also led to a marked reduction in production costs, which could then become a relatively small fraction of sales price for future products which are sold at prices at or near current levels. The reduction of capacity and cost pressures for current state-of-the-art bulk production processes may shift the focus of process development efforts and have important implications for both plant design and product development strategies for both biopharmaceutical and contract manufacturing companies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Production of recombinant protein therapeutics in cultivated mammalian cells
Wurm, F. M. (2004) · Nature Biotechnology · doi:10.1038/nbt1026 · Cited by 2,032
Downstream processing of monoclonal antibodies—Application of platform approaches
Shukla, A. A., Hubbard, B., Tressel, T., Guhan, S., & Low, D. (2007) · Journal of Chromatography B · doi:10.1016/j.jchromb.2006.09.026 · Cited by 876
Quality by Design in Biopharmaceuticals
Yang, H. (2016) · doi:10.1201/9781315371726-7 · Cited by 543
The cost of biopharmaceutical R&D: is biotech different?
DiMasi, J. A., & Grabowski, H. G. (2007) · Managerial and Decision Economics · doi:10.1002/mde.1360 · Cited by 517
Future of antibody purification
Low, D., O’Leary, R., & Pujar, N. S. (2007) · Journal of Chromatography B · doi:10.1016/j.jchromb.2006.10.033 · Cited by 472
Process economics of industrial monoclonal antibody manufacture
Farid, S. S. (2007) · Journal of Chromatography B · doi:10.1016/j.jchromb.2006.07.037 · Cited by 389
The Development Factory: Unlocking the Potential of Process Innovation
Pisano, G. P. (1996) · Cited by 353
Very Large Scale Monoclonal Antibody Purification: The Case for Conventional Unit Operations
Kelley, B. (2007) · Biotechnology Progress · doi:10.1021/bp070117s · Cited by 337
Self-citationFahrner, R. L., Knudsen, H. L., Basey, C. D., Galan, W., Feuerhelm, D., Vanderlaan, M., & Blank, G. S. (2001) · Biotechnology and Genetic Engineering Reviews · doi:10.1080/02648725.2001.10648017 · Cited by 259
Therapeutic antibody expression technology
Chadd, H. E., & Chamow, S. M. (2001) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(00)00198-1 · Cited by 204
Cited by
DNA Nanotechnology-Enabled Drug Delivery Systems
Hu, Q., Li, H., Wang, L., Gu, H., & Fan, C. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00663 · Cited by 1,118
Strategies and challenges for the next generation of therapeutic antibodies
Beck, A., Wurch, T., Bailly, C., & Corvaia, N. (2010) · Nature Reviews Immunology · doi:10.1038/nri2747 · Cited by 847
Therapeutic antibodies for autoimmunity and inflammation
Chan, A. C., & Carter, P. J. (2010) · Nature Reviews Immunology · doi:10.1038/nri2761 · Cited by 837
Cell culture processes for monoclonal antibody production
Li, F., Vijayasankaran, N., Shen, A. (., Kiss, R., & Amanullah, A. (2010) · mAbs · doi:10.4161/mabs.2.5.12720 · Cited by 739
Phillips, M. A., Burrows, J. N., Manyando, C., van Huijsduijnen, R. H., Van Voorhis, W. C., & Wells, T. N. C. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.50 · Cited by 649
Alternative molecular formats and therapeutic applications for bispecific antibodies
Spiess, C., Zhai, Q., & Carter, P. J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.003 · Cited by 607
DNA nanotechnology from the test tube to the cell
Chen, Y.-J., Groves, B., Muscat, R. A., & Seelig, G. (2015) · Nature Nanotechnology · doi:10.1038/nnano.2015.195 · Cited by 594
Agarwal, P., & Bertozzi, C. R. (2015) · Bioconjugate Chemistry · doi:10.1021/bc5004982 · Cited by 605
Recent advances in large-scale production of monoclonal antibodies and related proteins
Shukla, A. A., & Thömmes, J. (2010) · Trends in Biotechnology · doi:10.1016/j.tibtech.2010.02.001 · Cited by 578
Introduction to current and future protein therapeutics: A protein engineering perspective
Carter, P. J. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.02.013 · Cited by 467
Advances in recombinant antibody manufacturing
Kunert, R., & Reinhart, D. (2016) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-016-7388-9 · Cited by 417
A guide to manufacturing CAR T cell therapies
Vormittag, P., Gunn, R., Ghorashian, S., & Veraitch, F. S. (2018) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2018.01.025 · Cited by 383
Trends in Upstream and Downstream Process Development for Antibody Manufacturing
Gronemeyer, P., Ditz, R., & Strube, J. (2014) · Bioengineering · doi:10.3390/bioengineering1040188 · Cited by 329
Continuous downstream processing for high value biological products: A Review
Zydney, A. L. (2016) · Biotechnology and Bioengineering · doi:10.1002/bit.25695 · Cited by 302
Pollock, J., Ho, S. V., & Farid, S. S. (2013) · Biotechnology and Bioengineering · doi:10.1002/bit.24608 · Cited by 291
Perfusion mammalian cell culture for recombinant protein manufacturing – A critical review
Bielser, J.-M., Wolf, M., Souquet, J., Broly, H., & Morbidelli, M. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.04.011 · Cited by 263
Technology trends in antibody purification
Gagnon, P. (2012) · Journal of Chromatography A · doi:10.1016/j.chroma.2011.10.034 · Cited by 252
Erasmus, J. H., Archer, J., Fuerte-Stone, J., Khandhar, A. P., Voigt, E., Granger, B., Bombardi, R. G., Govero, J., Tan, Q., Durnell, L. A., et al. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.06.011 · Cited by 118
Development of broad‐spectrum human monoclonal antibodies for rabies post‐exposure prophylaxis
De Benedictis, P., Minola, A., Rota Nodari, E., Aiello, R., Zecchin, B., Salomoni, A., Foglierini, M., Agatic, G., Vanzetta, F., Lavenir, R., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505986 · Cited by 103
Ha, T. K., Kim, D., Kim, C. L., Grav, L. M., & Lee, G. M. (2022) · Biotechnology Advances · doi:10.1016/j.biotechadv.2021.107831 · Cited by 74
Mahal, H., Branton, H., & Farid, S. S. (2021) · Biotechnology and Bioengineering · doi:10.1002/bit.27774 · Cited by 71
Glycoengineering in CHO cells: advances in systems biology
Tejwani, V., Andersen, M. R., Nam, J. H., & Sharfstein, S. T. (2018) · Biotechnology Journal · doi:10.1002/biot.201700234 · Cited by 70
Perfusion culture of Chinese Hamster Ovary cells for bioprocessing applications
MacDonald, M. A., Nöbel, M., Roche Recinos, D., Martínez, V. S., Schulz, B. L., Howard, C. B., Baker, K., Shave, E., Lee, Y. Y., Marcellin, E., et al. (2022) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2021.1998821 · Cited by 55
Welles, H. C., Jennewein, M. F., Mason, R. D., Narpala, S., Wang, L., Cheng, C., Zhang, Y., Todd, J.-P., Lifson, J. D., Balazs, A. B., et al. (2018) · PLOS Pathogens · doi:10.1371/journal.ppat.1007395 · Cited by 53
Continuous integrated manufacturing for biopharmaceuticals: A new paradigm or an empty promise?
Rathore, A. S., Thakur, G., & Kateja, N. (2023) · Biotechnology and Bioengineering · doi:10.1002/bit.28235 · Cited by 41
Selas Castiñeiras, T., Williams, S. G., Hitchcock, A., Cole, J. A., Smith, D. C., & Overton, T. W. (2018) · Scientific Reports · doi:10.1038/s41598-018-25192-3 · Cited by 32
Current GMP standards for the large‐scale production of monoclonal antibodies
Troncoso‐Bravo, T., Pavez, V., Letelier, P., Del Río, J., Anabalón, C., Peñaloza, H. F., González, P. A., Bueno, S. M., & Kalergis, A. M. (2026) · Bioengineering & Translational Medicine · doi:10.1002/btm2.70121 · Cited by 2
Metadata
- Authors
- Kelley, B.
- Venue
- mAbs
- Publisher
- Informa UK Limited
- Published
- 2009-09
- Volume
- 1
- Issue
- 5
- Pages
- 443-452
- ISSN
- 1942-0862 (ISSN-L)
- 1942-0870
- OpenAlex
- W2134238361
- Cited by
- 667
- References
- 13
- FWCI
- 9.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.